Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

s compares to EUR 40.1 million in cash and EUR 6.7 million in short term investments at December 31, 2007. This level of cash resources is expected to allow ThromboGenics to drive forward its operational plans for the next two years.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics had a very successful 2008, making excellent progress with its development pipeline and reporting a pre-tax profit for the period. The recent start of our Phase III program with microplasmin in patients with back of the eye disease is a major milestone for the Company. Our decision to initiate this pivotal clinical program was driven by the excellent clinical Phase II data that we have generated, combined with our strong financial position. This is the result of the EUR30m upfront payment we received as part of our major strategic licensing deal for TB-403 with Roche, signed in June 2008. We are also making good progress with TB-402, a novel long acting anti-coagulant which we believe has advantages over currently marketed products. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools needed to ensure our corporate success."

For the full report of these results please go to http://www.thrombogenics.com

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... January 24 The European Commission has granted,marketing ... antidepressant for the treatment of adult patients,with major ... is still great scope for improved therapies to ... from Warneford,Hospital, Oxford, United Kingdom. "Valdoxan is an ...
... has launched www.EyeScience.com to fill a large ... macular degeneration (AMD) in a unique watch-and-learn video format. ... the leading cause of blindness in Americans age 50 ... basic eye anatomy, screening and diagnosis, risk factors, signs ...
... Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), today ... Jin Chuang Pharmaceutical Company ("Jin,Chuang"), signed an ...
Cached Biology Technology:Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 2Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe 3EyeScience Launches Comprehensive Online Resource Devoted to Age-Related Macular Degeneration Education and Prevention 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 2China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets 3
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... a colony of honeybees grows to about 4,000 members, ... cycle: the building of a special type of comb ... of experts from the Department of Neurobiology and Behaviour ... starts the reproductive cycle of honeybee colonies. The results ... Science of Nature . , Reproduction isn,t always ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Worker bees 'know' when to invest in their reproductive future 2
... of frozen methane deposits is the likely cause of a ... years ago, according to an international research team led by ... finding is expected to come as a relief to scientists ... might have been touched off by methane melts in the ...
... individuals around the world are alive because of him. ... to make the use of life-saving devices such as ... and heart-lung bypass systems almost commonplace. In the ... biomaterials leader. John Brash, P.Eng., director of the ...
... in preparing for how data from the Sentinel-1 European ... land-cover mapping and crop management. Sentinel-1 is the first ... the GMES initiative. Sentinel-1 is a constellation of ... day and night imagery for use in a range ...
Cached Biology News:Wetlands likely source of methane from ancient warming event 2Wetlands likely source of methane from ancient warming event 3Canadian biomedical engineering pioneer receives international award 2A glimpse of future GMES Sentinel-1 radar images 2
... contains choice of PDMS Stamps (3 PDMS ... 200 micron squares or 100 um x ... mm lines, 3 PDMS nano-patterned stamps with ... and pitch of 400 nm, or 3 ...
...
... The product contains 5 ml of DETACHaBEAD ... release mouse CD4+ T cells from Dynabeads ... mosue CD4+ T cells from Dynabeads Mouse ... cells are suitable for any downstream application ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: